Combination-ingredient ads: dosage form name and adjacent 502(n) quantities

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

This rule applies only to prescription-drug advertisements (as defined and reached by 21 CFR 202.1 — not promotional labeling or other non-advertisement materials) that use one proprietary name or designation to refer to a combination of active ingredients present in more than one preparation (the preparations differing in the quantities of active ingredients and/or the finished dosage form), where no established name corresponds to that proprietary name or designation. In that circumstance, the ad must (a) prominently display the name of at least one specific dosage form, and (b) place the section 502(n) quantitative ingredient information in direct conjunction with that display. This rule does not address any equal-prominence obligation for quantitative ingredient information of other, additional dosage forms listed in the same advertisement; that obligation is a separate rule triggered when the advertisement lists dosage forms in addition to the one used for this required display.

Check

First confirm the trigger: is this a prescription-drug advertisement (not promotional labeling or other non-advertisement piece) that uses a single proprietary name/designation for a combination of active ingredients spanning more than one preparation (differing in ingredient quantities and/or dosage form), with no corresponding established name? If so, verify (a) the name of at least one specific dosage form is prominently displayed somewhere in the ad, and (b) the section 502(n) quantitative ingredient information is placed in direct conjunction with that specific display of the dosage form name. Flag as a violation if either: (i) no specific dosage form name is prominently displayed anywhere in the advertisement, or (ii) the section 502(n) quantitative ingredient information is not in direct conjunction with that display — e.g., separated by intervening text or graphics, or placed on a different page or screen. Do not evaluate here whether other, additional dosage forms listed in the ad have equal-prominence quantitative information; that is a separate check.

Escalate when

Escalate when it is unclear whether the piece is an "advertisement" within the reach of 21 CFR 202.1 (as opposed to promotional labeling or other material outside its scope), or whether it actually meets the triggering condition (single proprietary name covering a multi-preparation combination with no established name). Also escalate when the prominence of the dosage form name is borderline, or when whether the quantitative ingredient information is "in direct conjunction" with that display is debatable (e.g., same page but visually separated, or ambiguous layout).

Where this comes from

21 CFR 202.1(d)(2), first sentence. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…on with the most prominent display of such proprietary name or designation. The prominence of this listing of active ingredients shall bear a reasonable relationship to the prominence of the proprietary name and the relationship between such proprietary name or designation, and the listing of active ingredients shall be made clear by use of such phrase as “brand of”, preceding the listing of active ingredients. (2) The advertisement shall prominently display the name of at least one specific dosage form and shall have the quantitative ingredient information required by section 502(n) of the act in direct conjunction with such display. If other dosage forms are listed in the advertisement, the quantitative ingredient information for such dosage forms shall appear in direct conjunction and in equal prominence with the most prominent listing of the names of such dosage forms. (e) True statement of information in brief summary relating to side effects, contraindications, and effectiveness: (1) When required. All advertisements for any prescriptio…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quoted sentence is a genuine mandatory obligation ('shall prominently display', 'shall have ... in direct conjunction'), not guidance or an example, so the underlying requirement is supported by the source.
- Scope is overstated. The quote is 21 CFR 202.1(d)(2), nested inside paragraph (d), whose opening subparagraph (d)(1) sets the triggering condition: an advertisement that 'employs one proprietary name or designation to refer to a combination of active ingredients present in more than one preparation ... and there is no established name corresponding to such proprietary name or designation.' 'The advertisement' in (d)(2) refers to that advertisement, not to every promotional piece. As written, applies_when = any 'promotional' material converts a narrow combination-product/no-established-name rule into a universal one.
- Scope is also overstated as to product type: § 202.1 governs prescription-drug advertisements (and by its own terms 'advertisements'), yet applies_when captures all promotional material with no limitation to prescription drug advertising.
- determinism is wrong. 'Prominently display' is an impression/prominence judgment (the same paragraph elsewhere speaks of prominence bearing 'a reasonable relationship'), and 'in direct conjunction with such display' turns on layout adequacy rather than a literal string match. The check itself asks the reviewer to confirm something is 'prominently displayed' and 'adjacent' — both judgment calls. This should be 'judgment'.
- authority = binding is correct: 21 CFR is a regulation.
- Locator 21 CFR 202.1(d)(2) matches the quoted sentence exactly.
- Atomicity is acceptable: the two clauses describe one integrated display requirement (dosage form name plus conjoined quantitative ingredient information) drawn from a single sentence, and the second clause is defined by reference to the first.
- Severity 'blocker' is defensible for an express regulatory 'shall' requirement, provided the applies_when trigger is corrected so the rule only fires on advertisements actually covered by paragraph (d).
- The rule omits the second sentence of (d)(2) (quantitative ingredient info for other listed dosage forms in direct conjunction and equal prominence). That is acceptable as a separate rule, but the title should not imply it covers all of (d)(2).
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the first sentence of 21 CFR 202.1(d)(2), an operative mandatory requirement ('shall prominently display... shall have the quantitative ingredient information... in direct conjunction'). The drafter correctly recognized that (d)(2) is not free-standing and imported the triggering condition from (d)(1) (one proprietary name/designation for a combination of active ingredients present in more than one preparation, preparations differing in quantities and/or finished dosage form, no corresponding established name). Citing the locator as (d)(1)-(2) is therefore appropriate, not an overreach.
- Authority correctly 'binding': this is codified regulation text, and the obligation is stated in mandatory 'shall' terms, not guidance.
- Determinism correctly 'judgment': 'prominently display', 'direct conjunction' and (for the second sentence) 'equal prominence' all turn on layout impression and relative prominence, which no literal match settles.
- Severity 'blocker' is defensible: non-compliance with a mandatory content/placement requirement of 202.1 renders the advertisement violative and is not curable by a caveat elsewhere in the piece.
- Not atomic: the rule statement covers only the first sentence of (d)(2) (prominent dosage form name + QI in direct conjunction), but the Check silently adds the second sentence's separate obligation — that QI for *other* listed dosage forms appear in direct conjunction and in equal prominence with the most prominent listing of those dosage-form names. That is an independently triggered and independently checkable requirement (it fires only when additional dosage forms are listed) and it is not reflected in the rule statement, so the Check tests more than the rule states.
- Overstated in the Check's flagging criteria: for the first-sentence requirement the source demands (i) prominent display of the dosage form name and (ii) QI in direct conjunction with that display. It does not impose any prominence-parity requirement on the QI relative to the dosage form name (the 'equal prominence' standard in (d)(2) attaches only to other listed dosage forms, and the 'reasonable relationship' standard in (c) and (d)(1) attaches to the proprietary-name display, not here). The Check's trigger 'materially smaller/less prominent presentation' therefore creates an obligation the quoted sentence does not contain.
- applies_when is coarser than the source: 202.1 governs prescription-drug *advertisements*, whereas the facet is set to generic 'promotional'. The rule statement does narrow this correctly in prose, so this is a labeling imprecision rather than a substantive defect, but the advertisement-only scope should not be lost if the facet is read on its own.
- The Check's gloss on 'direct conjunction' (separated by intervening text/graphics, different page or screen) is a fair reading of the regulation's placement language and is not a ground for withholding a pass.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is verbatim the first sentence of 21 CFR 202.1(d)(2) and states a mandatory obligation ('shall prominently display… and shall have… in direct conjunction'), so the rule statement follows directly from operative regulatory text, not from an example, definition, or preamble.
- The trigger conditions in the rule (one proprietary name/designation for a combination of active ingredients present in more than one preparation, preparations differing in quantities and/or finished dosage form, no corresponding established name) are taken from the opening conditional of (d)(1). Since (d)(1) and (d)(2) are subdivisions of the same conditional paragraph (d), and (d)(2) refers to 'The advertisement' posited in (d)(1), carrying that trigger into (d)(2) is the correct structural reading rather than an invented limit.
- No overstatement: 'shall' is rendered as an obligation, not softened or hardened; the rule is confined to prescription-drug advertisements within the reach of § 202.1, matching the section heading and its consistent use of 'the advertisement', and does not extend to promotional labeling generally.
- Scope discipline is good: the rule expressly excludes the second sentence of (d)(2) (equal-prominence quantitative information for additional dosage forms) and assigns it to a separate rule, and it does not absorb (d)(1)'s own established-names-listing obligation.
- Atomic: the two elements are one compound obligation from a single sentence. Element (b) is defined by reference to 'such display' and is vacuous absent element (a), so they are not independently standing requirements; splitting would produce an unevaluable fragment.
- Determinism 'judgment' is correct — 'prominently display' and 'in direct conjunction' turn on prominence, adjacency, and visual layout, which cannot be settled by literal match or mere presence/absence.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified regulation.
- Locator '21 CFR 202.1(d)(2), first sentence' precisely identifies the quoted sentence.
- Severity 'blocker' is defensible: failure to meet a mandatory § 202.1 content-and-placement requirement renders the advertisement violative and is not something a reviewer can pass with comments.
- applies_when is coarse (only 'promotional') and does not encode the advertisement-vs-labeling limit or the combination-product trigger, but both limits are stated explicitly in the rule statement and as the mandatory first step of the check, so the rule cannot be misapplied outside its scope; this is a schema granularity issue, not a substantive defect.
- The check's examples of failing 'direct conjunction' (intervening text or graphics, different page or screen) are consistent with the adjacency standard used elsewhere in the same section, e.g., (a)(1)'s 'without any intervening written, printed, or graphic matter' and the 'direct conjunction' usage in (b)(1) and (c); they are framed as examples, and the escalate-when clause properly routes borderline prominence and conjunction calls to a human.